Abstract
MicroRNAs (miRNAs) are RNA molecules at about 22 nucleotide in length that are non-coding, which regulate gene expression in the post-transcriptional level by performing degradation or blocks translation of the target mRNA. It is known that they play roles in mechanisms such as metabolic regulation, embryogenesis, organogenesis, differentiation and growth control by providing post-transcriptional regulation of gene expression. With these properties, miRNAs play important roles in the regulation of biological processes such as proliferation, differentiation, apoptosis, drug resistance mechanisms in eukaryotic cells. In addition, there are miRNAs that can be used for cancer therapy. Tumor cells and tumor microenvironment have different miRNA expression profiles. Some miRNAs are known to play a role in the onset and progression of the tumor. miRNAs with oncogenic or tumor suppressive activity specific to different cancer types are still being investigated. This review summarizes the role of miRNAs in tumorigenesis, therapeutic strategies in human cancer and current studies.
Similar content being viewed by others
Abbreviations
- miRNA:
-
MicroRNA
- RISC:
-
RNA-induced silencing complex
- oncomiR:
-
Oncogenic miRNA
- tsmiR:
-
Tumor suppressor miRNA
- UTR:
-
Unstranslated region(s)
- anti-miR(s):
-
Anti-miRNA oligonucleotides
- NSCLC:
-
Non-small-cell lung cancer
- antagomiR(s):
-
miRNA antagonists
- PTEN:
-
Phosphatase and tensin homolog
- VEGF:
-
Vascular epidermal growth factor
- SOCS1:
-
Suppressor of cytokine signaling 1
- AMOs:
-
Anti-miRNA oligonucleotides
- HCN1:
-
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1
References
Abba ML, Patil N, Leupold JH et al (2017) MicroRNAs as novel targets and tools in cancer therapy. Cancer Lett 387:84–94
An Z, Ren J, Yang G et al (2015) MicroRNA let-7: regulation, single nucleotide polymorphism, and therapy in lung cancer. J Cancer Res Ther 11:1. https://doi.org/10.4103/0973-1482.163830
Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A (2013) The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer 108:2573. https://doi.org/10.1038/bjc.2013.250
Babar IA, Cheng CJ, Booth CJ et al (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci 109:E1695–E1704. https://doi.org/10.1073/pnas.1201516109
Babashah S, Soleimani M (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 47:1127–1137. https://doi.org/10.1016/j.ejca.2011.02.008
Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126
Bai S, Tian B, Li A et al (2016) MicroRNA-125b promotes tumor growth and suppresses apoptosis by targeting DRAM2 in retinoblastoma. Eye 30:1630–1638. https://doi.org/10.1038/eye.2016.189
Barger JF, Nana-Sinkam SP (2015) MicroRNA as tools and therapeutics in lung cancer. Respir Med 109:803–812. https://doi.org/10.1016/j.rmed.2015.02.006
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Bhatnagar N, Li X, Padi SKR et al (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:e105. https://doi.org/10.1038/cddis.2010.85
Cai ZK, Chen Q, Chen YB et al (2015) microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7. Mol Med Rep 11:533–538. https://doi.org/10.3892/mmr.2014.2744
Castro D, Moreira M, Gouveia AM et al (2017) MicroRNAs in lung cancer. Oncotarget 8:81679–81685. https://doi.org/10.18632/oncotarget.20955
Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029–6033. https://doi.org/10.1158/0008-5472.CAN-05-0137
Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267–274
Chen ML, Sen Liang L, Wang XK (2012) MiR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin Exp Metastasis 29:457–469. https://doi.org/10.1007/s10585-012-9463-7
Chen J, Wang W, Zhang Y et al (2014a) The roles of miR-200c in colon cancer and associated molecular mechanisms. Tumor Biol 35:6475–6483. https://doi.org/10.1007/s13277-014-1860-x
Chen XN, Wang KF, Xu ZQ et al (2014b) MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int 14:70. https://doi.org/10.1186/s12935-014-0070-3
Chen Z, Li D, Cheng Q et al (2014c) MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2. Mol Med Rep 9:503–508. https://doi.org/10.3892/mmr.2013.1814
Chen S, Jiao JW, Sun KX et al (2015) MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther 9:5225–5235. https://doi.org/10.2147/DDDT.S87526
Chen W, Huang L, Hao C et al (2016) MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells. Tumor Biol 37:9289–9299. https://doi.org/10.1007/s13277-016-4804-9
Chen GM, Zheng AJ, Cai J et al (2018a) microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway. J Cell Biochem 119:885–895. https://doi.org/10.1002/jcb.26252
Chen L, Cao H, Feng Y (2018b) MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J Urol 36:357–365. https://doi.org/10.1007/s00345-017-2143-0
Cheng CJ, Bahal R, Babar IA et al (2014) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518:107–110. https://doi.org/10.1038/nature13905
Chiang CH, Hou MF, Hung WC (2013) Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta Gen Subj 1830:3067–3076. https://doi.org/10.1016/j.bbagen.2013.01.009
Choi WY, Giraldez AJ, Schier AF (2007) Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430. Science 318:271–274. https://doi.org/10.1126/science.1147535
Christopher A, Kaur R, Kaur G et al (2016) MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect Clin Res 7:68. https://doi.org/10.4103/2229-3485.179431
Cui Y, Wu F, Tian D et al (2018) MiR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol Rep 39:1649–1657. https://doi.org/10.3892/or.2018.6259
Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16:861–865. https://doi.org/10.1016/j.molcel.2004.12.002
de Melo Maia B, Ling H, Monroig P et al (2015) Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. Mol Cell Probes 29:420–426. https://doi.org/10.1016/j.mcp.2015.08.002
Denli AM, Tops BBJ, Plasterk RH et al (2004) Processing of primary microRNAs by the microprocessor complex. Nature 432:231–235. https://doi.org/10.1038/nature03049
Dey N, Das F, Ghosh-Choudhury N et al (2012) MicroRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS ONE 6:e37366. https://doi.org/10.1371/journal.pone.0037366
Ding Y, Wu M, Liu J et al (2014) Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. Exp Eye Res 122:1–8. https://doi.org/10.1016/j.exer.2014.02.017
Dybos SA, Flatberg A, Halgunset J et al (2018) Increased levels of serum miR-148a-3p are associated with prostate cancer. APMIS 126:722–731. https://doi.org/10.1111/apm.12880
Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16:2043–2050. https://doi.org/10.1261/rna.2414110
Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726. https://doi.org/10.1038/nmeth1079
Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269. https://doi.org/10.1038/nrc1840
Fan Y, Song X, Du H et al (2014) Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3 K-AKT pathway. Med Oncol 31:65. https://doi.org/10.1007/s12032-014-0065-x
Fan L, Li M, Wang S et al (2015) Targeted inhibition of microRNA-200c on expression of AP-2α to enhance the proliferation of colon cancer cells in vitro. Cancer Res Clin 27:222–227. https://doi.org/10.3760/cma.j.issn.1006-9801.2015.04.002
Feng X, Liu N, Deng S et al (2017) Mir-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1α. Onco Targets Ther 10:5899–5906. https://doi.org/10.2147/OTT.S145833
Fernandez S, Risolino M, Mandia N et al (2014) miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene 34:3240. https://doi.org/10.1038/onc.2014.267
Ferracin M, Bassi C, Pedriali M et al (2013) MiR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer. 12:130. https://doi.org/10.1186/1476-4598-12-130
Garofalo M, Croce CM (2013) MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 16:47–59. https://doi.org/10.1016/j.drup.2013.05.001
Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775
Giunti L, Da Ros M, Vinci S et al (2015) Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am J Cancer Res 5:231–242
Gong P, Zhang T, He D, Hsieh J-T (2015) MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer. Radiat Res 184:630–638. https://doi.org/10.1667/RR14185.1
González-Vallinas M, Molina S, Vicente G et al (2014) Expression of MicroRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of rosemary diterpenes in colon and pancreatic cancer. PLoS ONE 9:e98556. https://doi.org/10.1371/journal.pone.0098556
Gregory RI, Yan K-P, Amuthan G et al (2004) The microprocessor complex mediates the genesis of microRNAs. Nature 432:235–240. https://doi.org/10.1038/nature03120
Gui ZL, Wu TL, Zhao GC et al (2017) MicroRNA-497 suppress osteosarcoma by targeting MAPK/Erk pathway. Bratislava Med J 118:449–452. https://doi.org/10.4149/BLL_2017_087
Guo Y, Liu H, Zhang H et al (2012) miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. Oncol Lett 4:561–565. https://doi.org/10.3892/ol.2012.775
Haghnavaz N, Asghari F, Elieh Ali Komi D et al (2018) HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. Artif Cells Nanomed Biotechnol 46:518–523. https://doi.org/10.1080/21691401.2017.1326927
Han C, Zhou Y, An Q et al (2015) MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. Tumor Biol 36:6715–6723. https://doi.org/10.1007/s13277-015-3358-6
Hu Q, Chen WX, Zhong SL et al (2014) MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumor Biol 35:6327–6334. https://doi.org/10.1007/s13277-014-1834-z
Huang YW, Kuo CT, Chen JH et al (2014) Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol 133:340–345. https://doi.org/10.1016/j.ygyno.2014.02.009
Ibrahim AF, Weirauch U, Thomas M et al (2011) MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71:5214–5224. https://doi.org/10.1158/0008-5472.CAN-10-4645
Inamura K, Ishikawa Y (2016) MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med 5:36. https://doi.org/10.3390/jcm5030036
Jang MH, Kim HJ, Gwak JM et al (2017) Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol 68:69–78. https://doi.org/10.1016/j.humpath.2017.08.026
Janssen HLA, Reesink HW, Lawitz EJ et al (2013) Treatment of HCV infection by targeting MicroRNA. N Engl J Med 368:1685–1694. https://doi.org/10.1056/NEJMoa1209026
Jeker LT, Bluestone JA (2013) MicroRNA regulation of T-cell differentiation and function. Immunol Rev 253:65–81
Ji W, Sun B, Su C (2017) Targeting microRNAs in cancer gene therapy. Genes (Basel) 8:21
Jiang L, Yu L, Zhang X et al (2016) MiR-892b silencing activates NF-kB and promotes aggressiveness in breast cancer. Cancer Res 76:1101–1111. https://doi.org/10.1158/0008-5472.CAN-15-1770
Jin W, Chen F, Wang K et al (2018) miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-β signaling pathway. Biomed Pharmacother 104:637–644. https://doi.org/10.1016/j.biopha.2018.05.041
Kasinski AL, Slack FJ (2012) MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72:5576–5587. https://doi.org/10.1158/0008-5472.CAN-12-2001
Kim SJ, Oh JS, Shin JY et al (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155:427–434. https://doi.org/10.1016/j.jconrel.2011.06.026
Kinose Y, Sawada K, Nakamura K, Kimura T (2014) The role of microRNAs in ovarian cancer. Biomed Res Int 2014:249393. https://doi.org/10.1155/2014/249393
Kluiver J, Gibcus JH, Hettinga C et al (2012) Rapid generation of microRNA sponges for microRNA inhibition. PLoS ONE 7:e29275. https://doi.org/10.1371/journal.pone.0029275
Kneitz B, Krebs M, Kalogirou C et al (2014) Survival in patients with high-risk prostate cancer is predicted by mir-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 74:2591–2603. https://doi.org/10.1158/0008-5472.CAN-13-1606
Kroesen BJ, Teteloshvili N, Smigielska-Czepiel K et al (2015) Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology 144:1–10. https://doi.org/10.1111/imm.12367
Krützfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with “antagomirs”. Nature 438:685. https://doi.org/10.1038/nature04303
Larne O, Hagman Z, Lilja H et al (2015) miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis 36:858–866. https://doi.org/10.1093/carcin/bgv063
Lee JW, Park YA, Choi JJ et al (2011) The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol 120:56–62. https://doi.org/10.1016/j.ygyno.2010.09.022
Lei C, Du F, Sun L et al (2017) MIR-143 & MIR-145 inhibit gastric cancer cell migration & metastasis by suppressing MYO6. Cell Death Dis 8:e3101. https://doi.org/10.1038/cddis.2017.493
Li F, Mahato RI (2014) MicroRNAs and drug resistance in prostate cancers. Mol Pharm 11:2539–2552. https://doi.org/10.1021/mp500099g
Li C, Feng Y, Coukos G, Zhang L (2009) Therapeutic microRNA strategies in human cancer. AAPS J 11:747–757. https://doi.org/10.1208/s12248-009-9145-9
Li N, Li X, Huang S et al (2013) MiR-126 inhibits colon cancer proliferation and invasion through targeting IRSI, SLC7A5 and TOMI gene. J Cent South Univ Med Sci 38:809–817. https://doi.org/10.3969/j.issn.1672-7347.2013.08.009
Li B, Ren S, Li X et al (2014a) MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 83:146–153. https://doi.org/10.1016/j.lungcan.2013.11.003
Li L, Zhou L, Li Y et al (2014b) MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. J BUON 19:228–236
Li N, Yang L, Wang H et al (2015) MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS ONE 10:e0128886. https://doi.org/10.1371/journal.pone.0128886
Li C, Xu N, Li YQ et al (2016) Inhibition of SW620 human colon cancer cells by upregulating miRNA-145 basic study. World J Gastroenterol 22:2771–2778. https://doi.org/10.3748/wjg.v22.i9.2771
Li B, Jin X, Meng H et al (2017a) Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget 8:47849. https://doi.org/10.18632/oncotarget.18133
Li B, Wang W, Li Z et al (2017b) MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett 410:212–227. https://doi.org/10.1016/j.canlet.2017.09.035
Li B, Ding CM, Li YX et al (2018) MicroRNA-145 inhibits migration and induces apoptosis in human non-small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway. Oncol Rep 40:2944–2954. https://doi.org/10.3892/or.2018.6666
Liang A-L, Zhang T-T, Zhou N et al (2016) miRNA-10b sponge: an anti-breast cancer study in vitro. Oncol Rep 35:1950–1958. https://doi.org/10.3892/or.2016.4596
Lin PC, Chiu YL, Banerjee S et al (2013) Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 73:1–13. https://doi.org/10.1158/0008-5472.CAN-12-2968
Lin HM, Nikolic I, Yang J et al (2018) MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci Rep 8:7820. https://doi.org/10.1038/s41598-018-26050-y
Liu M, Chen H (2010) The role of microRNAs in colorectal cancer. J Genet Genom 37:347–358. https://doi.org/10.1016/S1673-8527(09)60053-9
Liu X, Li G (2015) MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor. Int J Clin Exp Pathol 8:10605–10614. https://doi.org/10.1001/archderm.1991.01680020078009
Liu C, Kelnar K, Liu B et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211. https://doi.org/10.1038/nm.2284
Liu Y, Lai L, Chen Q et al (2012) MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 188:5500–5510. https://doi.org/10.4049/jimmunol.1103505
Liu Y, Cui H, Wang W et al (2013) Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. Int J Biochem Cell Biol 45:2643–2650. https://doi.org/10.1016/j.biocel.2013.09.003
Liu K, Zhang C, Li T et al (2015) Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol 46:2526–2534. https://doi.org/10.3892/ijo.2015.2949
Liu Z, Wang C, Jiao X et al (2016) miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFκB. Am J Transl Res 8:4764–4777. https://doi.org/10.1007/978-3-319-20741-4_1
Lund E, Güttinger S, Calado A et al (2004) Nuclear export of microRNA precursors. Science 303:95–98. https://doi.org/10.1126/science.1090599
Ma L, Reinhardt F, Pan E et al (2010a) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28:341. https://doi.org/10.1038/nbt.1618
Ma L, Young J, Prabhala H et al (2010b) MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:247–256. https://doi.org/10.1038/ncb2024
Mak CSL, Yung MMH, Hui LMN et al (2017) MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 16:11. https://doi.org/10.1186/s12943-017-0582-2
Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I et al (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34:163–169. https://doi.org/10.3233/DMA-120957
Mataki H, Seki N, Mizuno K et al (2016) Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget 7:72084–72098. https://doi.org/10.18632/oncotarget.12290
McLeod BW, Hayman ML, Purcell AL et al (2011) The “real world” utility of miRNA patents: lessons learned from expressed sequence tags. Nat Biotechnol 29:129. https://doi.org/10.1038/nbt.1765
Mei Z, He Y, Feng J et al (2014) MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2. FEBS Lett 588:3055–3061. https://doi.org/10.1016/j.febslet.2014.06.020
Migita K, Iwanaga N, Izumi Y et al (2017) TNF-α-induced miR-155 regulates IL-6 signaling in rheumatoid synovial fibroblasts. BMC Res Notes 10:403. https://doi.org/10.1186/s13104-017-2715-5
Mignacca L, Saint-Germain E, Benoit A et al (2016) Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine 82:80–86. https://doi.org/10.1016/j.cyto.2016.01.015
Mo X, Zhang F, Liang H et al (2014) miR-544a promotes the invasion of lung cancer cells by targeting cadherina 1 in vitro. Onco Targets Ther 7:895–900. https://doi.org/10.2147/OTT.S61695
Mohammadi-Yeganeh S, Paryan M, Arefian E et al (2016) MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumor Biol 37:8993–9000. https://doi.org/10.1007/s13277-015-4513-9
Muhammad N, Bhattacharya S, Steele R, Ray RB (2016) Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget 7:58595. https://doi.org/10.18632/oncotarget.11193
Naidu S, Magee P, Garofalo M (2015) MiRNA-based therapeutic intervention of cancer. J Hematol Oncol 8:68. https://doi.org/10.1186/s13045-015-0162-0
Nedaeinia R, Sharifi M, Avan A et al (2016) Locked nucleic acid anti-MIR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-MIR as a novel approach. Cancer Gene Ther 23:246–253. https://doi.org/10.1038/cgt.2016.25
O’Day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12:201. https://doi.org/10.1186/bcr2484
Obad S, Dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371. https://doi.org/10.1038/ng.786
Paik WH, Kim HR, Park JK et al (2013) Chemosensitivity induced by down-regulation of MicroRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res 33:1473–1482. https://doi.org/10.1016/S1007-4376(07)60079-3
Pan Q, Meng L, Ye J et al (2017) Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial–mesenchymal transition (EMT). Cancer Lett 392:26–38. https://doi.org/10.1016/j.canlet.2017.01.039
Park JK, Kogure T, Nuovo GJ et al (2011) miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 71:7608–7616. https://doi.org/10.1158/0008-5472.CAN-11-1144
Pendlebury A, Hannan NJ, Binder N et al (2017) The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer. Biomed Rep 6:319–322. https://doi.org/10.3892/br.2017.847
Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17:118–126. https://doi.org/10.1016/j.tcb.2006.12.007
Pineau P, Volinia S, McJunkin K et al (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci 107:264–269. https://doi.org/10.1073/pnas.0907904107
Pramanik D, Campbell NR, Karikari C et al (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10:1470–1480. https://doi.org/10.1158/1535-7163.mct-11-0152
Qin X, Yan L, Zhao X et al (2012) microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett 4:1290–1296. https://doi.org/10.3892/ol.2012.896
Qin W-W, Zhang R, Chen R-A et al (2016) MicroRNA-145 induces cell cycle arrest in G1 phase by directly targeting KLF5 in colon cancer. Int J Clin Exp Pathol 9:5197–5209
Qu F, Zheng J, Gan W et al (2017) MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1. Oncotarget 8:52465
Querfeld C, Pacheco T, Foss FM et al (2016) Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood 128:1829
Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203
Sachdeva M, Zhu S, Wu F et al (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci 106:3207–3212. https://doi.org/10.1073/pnas.0808042106
Shah MY, Ferrajoli A, Sood AK et al (2016) microRNA therapeutics in cancer—an emerging concept. EBioMedicine 12:34–42
Shao XJ, Miao MH, Xue J et al (2015) The down-regulation of microRNA-497 contributes to cell growth and cisplatin resistance through PI3K/Akt pathway in osteosarcoma. Cell Physiol Biochem 36:2051–2062. https://doi.org/10.1159/000430172
Sharma S, Rajendran V, Kulshreshtha R, Ghosh PC (2017) Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells. Int J Pharm 530:387–400. https://doi.org/10.1016/j.ijpharm.2017.07.079
Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378. https://doi.org/10.1007/s10555-009-9188-5
Shi M, Liu D, Duan H et al (2010) Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 29:785–799. https://doi.org/10.1007/s10555-010-9265-9
Shi Z, Li Y, Qian X et al (2017) MiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressions. J Cancer 8:3037–3048. https://doi.org/10.7150/JCA.19315
Skjefstad K, Johannessen C, Grindstad T et al (2018) A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Sci Rep 8:8549. https://doi.org/10.1038/s41598-018-26864-w
Sulaiman SA, Ab Mutalib NS, Jamal R (2016) MiR-200c regulation of metastases in ovarian cancer: potential role in epithelial and mesenchymal transition. Front Pharmacol 7:271
Sun T, Wang X, He HH et al (2014) MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33:2790–2800. https://doi.org/10.1038/onc.2013.230
Tao Z, Xu S, Ruan H et al (2018) MiR-195/-16 family enhances radiotherapy via T cell activation in the tumor microenvironment by blocking the PD-L1 immune checkpoint. Cell Physiol Biochem 48:801–814. https://doi.org/10.1159/000491909
Teng Y, Manavalan TT, Hu C et al (2013) Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells. Toxicol Sci 131:71–83. https://doi.org/10.1093/toxsci/kfs290
Trang P, Wiggins JF, Daige CL et al (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19:1116–1122. https://doi.org/10.1038/mt.2011.48
Valeri N, Gasparini R, Nuovo G et al (2012) Anti-miR-135b in colon cancer treatment. J Clin Oncol 30:457
van Rooij E, Kauppinen S (2014) Development of microRNA therapeutics is coming of age. EMBO Mol Med 6:851–864. https://doi.org/10.15252/emmm.201100899
Wagenaar TR, Zabludoff S, Ahn S-M et al (2015) Anti-miR-21 suppresses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol Cancer Res 13:1009–1021. https://doi.org/10.1158/1541-7786.MCR-14-0703
Wang XY (2014) MiR-126 inhibits colon cancer proliferation and invasion by targeting CXCR4/Rho A signaling pathway. J Dig Dis 15:171
Wang ZX, Bin LuB, Wang H et al (2011) MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 42:281–290. https://doi.org/10.1016/j.arcmed.2011.06.008
Wang Z, Ting Z, Li Y et al (2013) microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol Lett 6:789–794. https://doi.org/10.3892/ol.2013.1448
Wang L, Gao W, Hu F et al (2014) MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9. FEBS Lett 588:4527–4535. https://doi.org/10.1016/j.febslet.2014.09.035
Wang L, Liu C, Li C et al (2015) Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. Gene 572:252–258. https://doi.org/10.1016/j.gene.2015.07.017
Wang L, Gao H, Gong N, Gong M (2016a) Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma. Exp Ther Med 12:3761–3766. https://doi.org/10.3892/etm.2016.3838
Wang L, Wang YX, Zhang DZ et al (2016b) Let-7a mimic attenuates CCL18 induced breast cancer cell metastasis through Lin 28 pathway. Biomed Pharmacother 78:301–307. https://doi.org/10.1016/j.biopha.2016.01.028
Wei L, Ran F (2018) MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma. Oncol Lett 15:271–277. https://doi.org/10.3892/ol.2017.7299
Weidle UH, Birzele F, Kollmorgen G, Nopora A (2018) Potential microRNA-related targets for therapeutic intervention with ovarian cancer metastasis. Cancer Genom Proteom 15:1–15
Wu Z, Liu K, Wang Y et al (2015) Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int 15:107. https://doi.org/10.1186/s12935-015-0235-8
Wu H, Zhou J, Mei S et al (2017) Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med 21:1228–1236. https://doi.org/10.1111/jcmm.13056
Xiao J, Yang B, Lin H et al (2007) Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212:285–292. https://doi.org/10.1002/jcp.21062
Xie Y, Todd NW, Liu Z et al (2010) Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67:170–176. https://doi.org/10.1016/j.lungcan.2009.04.004
Xu Q, Liu L-Z, Qian X et al (2012) MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40:761–774. https://doi.org/10.1093/nar/gkr730
Xu F, Zhang Q, Cheng W et al (2013a) Effect of miR-29b-1* and miR-29c knockdown on cell growth of the bladder cancer cell line T24. J Int Med Res 41:1803–1810. https://doi.org/10.1177/0300060513505266
Xu G, Zhang Y, Wei J et al (2013b) MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer 13:469. https://doi.org/10.1186/1471-2407-13-469
Xu X, Ayub B, Liu Z et al (2014) Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice. Mol Cancer Ther 13:1729–1739. https://doi.org/10.1158/1535-7163.MCT-13-0982
Xu Y, Chao L, Wang J, Sun Y (2017) miRNA-148a regulates the expression of the estrogen receptor through DNMT1-mediated DNA methylation in breast cancer cells. Oncol Lett 14:4736–4740. https://doi.org/10.3892/ol.2017.6803
Xu T, Du XW, Hu JB et al (2018) Anticancer effect of miR-96 inhibitor in bladder cancer cell lines. Oncol Lett 15:3814–3819. https://doi.org/10.3892/ol.2018.7745
Yan LX, Wu QN, Zhang Y et al (2011) Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13:R2. https://doi.org/10.1186/bcr2803
Yang X, Cai H, Liang Y et al (2015a) Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. Oncol Rep 33:1723–1730. https://doi.org/10.3892/or.2015.3757
Yang Y, Meng H, Peng Q et al (2015b) Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer Gene Ther 22:23. https://doi.org/10.1038/cgt.2014.66
Yang L, Hou J, Cui X-H et al (2017) MiR-133b regulates the expression of CTGF in epithelial-mesenchymal transition of ovarian cancer. Eur Rev Med Pharmacol Sci 21:5602–5609. https://doi.org/10.26355/eurrev_201712_14001
Yin XZ, Zhao DM, Zhang GX, Liu L (2016) Effect of miRNA-203 on cervical cancer cells and its underlying mechanism. Genet Mol Res. https://doi.org/10.4238/gmr.15038680
Yoo B, Kavishwar A, Ross A et al (2015) Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res 75:4407–4415. https://doi.org/10.1158/0008-5472.can-15-0888
Yu L, Todd NW, Xing L et al (2010) Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127:2870–2878. https://doi.org/10.1002/ijc.25289
Yu CC, Tsai LL, Wang ML et al (2013) MiR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 73:3425–3440. https://doi.org/10.1158/0008-5472.CAN-12-3840
Yu Y, Nangia-Makker P, Farhana L et al (2015) miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer 14:98. https://doi.org/10.1186/s12943-015-0372-7
Yu X, Li R, Shi W et al (2016) Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother 77:37–44. https://doi.org/10.1016/j.biopha.2015.11.005
Yuan W, Guo Y-Q, Li X-Y et al (2016) MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway. Oncotarget 7:60230. https://doi.org/10.18632/oncotarget.11176
Yuan J, Ji H, Xiao F et al (2017) MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1. Biochem Biophys Res Commun 483:578–584. https://doi.org/10.1016/j.bbrc.2016.12.102
Zhang Y, Lin Q (2015) MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. Int J Clin Exp Med 8:8794–8802
Zhang H, Pu J, Qi T et al (2012) MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 33:387. https://doi.org/10.1038/onc.2012.574
Zhang W-C, Liu J, Xu X, Wang G (2013a) The role of microRNAs in lung cancer progression. Med Oncol 30:675. https://doi.org/10.1007/s12032-013-0675-8
Zhang X, Huang L, Zhao Y, Tan W (2013b) Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai) 45:995–1001. https://doi.org/10.1093/abbs/gmt113
Zhang C, Liu K, Li T et al (2016) MiR-21: a gene of dual regulation in breast cancer. Int J Oncol 48:161–172. https://doi.org/10.3892/ijo.2015.3232
Zhang Q, Feng Y, Liu P, Yang J (2017) MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. Tumor Biol 39:1–8. https://doi.org/10.1177/1010428317711312
Zhao X, Li J, Huang S et al (2015) MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer. Am J Transl Res 7:1382–1389
Zhao C, Zhao Q, Zhang C et al (2017) MiR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis. Sci Rep 7:4194. https://doi.org/10.1038/s41598-017-04172-z
Zheng M, Sun X, Li Y, Zuo W (2015) MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol 37:8189–8196. https://doi.org/10.1007/s13277-015-4722-2
Zhou Y, Wu D, Tao J et al (2013) MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47:423–432. https://doi.org/10.3109/00365599.2012.748821
Zidan HE, Abdul-Maksoud RS, Elsayed WSH, Desoky EAM (2018) Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer. IUBMB Life 70:437–444
Zierau O, Helle J, Schadyew S et al (2018) Role of miR-203 in estrogen receptor-mediated signaling in the rat uterus and endometrial carcinoma. J Cell Biochem 119:5359–5372. https://doi.org/10.1002/jcb.26675
Zong C, Wang J, Shi TM (2014) MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumor Biol 35:12151–12156. https://doi.org/10.1007/s13277-014-2520-x
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ors-Kumoglu, G., Gulce-Iz, S. & Biray-Avci, C. Therapeutic microRNAs in human cancer. Cytotechnology 71, 411–425 (2019). https://doi.org/10.1007/s10616-018-0291-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-018-0291-8